PL3033101T3 - Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu - Google Patents
Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabuInfo
- Publication number
- PL3033101T3 PL3033101T3 PL14835826T PL14835826T PL3033101T3 PL 3033101 T3 PL3033101 T3 PL 3033101T3 PL 14835826 T PL14835826 T PL 14835826T PL 14835826 T PL14835826 T PL 14835826T PL 3033101 T3 PL3033101 T3 PL 3033101T3
- Authority
- PL
- Poland
- Prior art keywords
- benralizumab
- asthma
- methods
- exacerbation rates
- reducing exacerbation
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title 1
- 229950000321 benralizumab Drugs 0.000 title 1
- 230000005713 exacerbation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Bathtubs, Showers, And Their Attachments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864944P | 2013-08-12 | 2013-08-12 | |
| PCT/US2014/050080 WO2015023504A1 (en) | 2013-08-12 | 2014-08-07 | Methods for reducing exacerbation rates of asthma using benralizumab |
| EP14835826.0A EP3033101B1 (en) | 2013-08-12 | 2014-08-07 | Methods for reducing exacerbation rates of asthma using benralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3033101T3 true PL3033101T3 (pl) | 2019-06-28 |
Family
ID=52448837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14835826T PL3033101T3 (pl) | 2013-08-12 | 2014-08-07 | Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9441037B2 (pl) |
| EP (1) | EP3033101B1 (pl) |
| JP (4) | JP6746495B2 (pl) |
| KR (2) | KR102390714B1 (pl) |
| CN (2) | CN111588848A (pl) |
| AU (2) | AU2014306956B2 (pl) |
| BR (1) | BR112016002401A8 (pl) |
| CA (1) | CA2918105C (pl) |
| CY (1) | CY1122132T1 (pl) |
| DK (1) | DK3033101T3 (pl) |
| ES (1) | ES2716906T3 (pl) |
| HK (2) | HK1221644A1 (pl) |
| HR (1) | HRP20190405T1 (pl) |
| HU (1) | HUE042607T2 (pl) |
| LT (1) | LT3033101T (pl) |
| ME (1) | ME03348B (pl) |
| MX (1) | MX368508B (pl) |
| PL (1) | PL3033101T3 (pl) |
| PT (1) | PT3033101T (pl) |
| RS (1) | RS58404B1 (pl) |
| RU (1) | RU2676333C2 (pl) |
| SG (2) | SG10202005560UA (pl) |
| SI (1) | SI3033101T1 (pl) |
| SM (1) | SMT201900163T1 (pl) |
| TR (1) | TR201903312T4 (pl) |
| WO (1) | WO2015023504A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2918050C (en) * | 2013-08-12 | 2023-10-03 | Medimmune, Llc | Methods for improving asthma symptoms using benralizumab |
| PL3033104T3 (pl) * | 2013-08-12 | 2019-09-30 | Astrazeneca Ab | Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu |
| SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| WO2015061584A1 (en) * | 2013-10-24 | 2015-04-30 | Medimmune, Llc | Stable, aqueous antibody formulations |
| WO2015106080A2 (en) | 2014-01-10 | 2015-07-16 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| US10846696B2 (en) | 2015-08-24 | 2020-11-24 | Samsung Electronics Co., Ltd. | Apparatus and method for trusted execution environment based secure payment transactions |
| US10699274B2 (en) | 2015-08-24 | 2020-06-30 | Samsung Electronics Co., Ltd. | Apparatus and method for secure electronic payment |
| HK1255922A1 (zh) | 2015-11-04 | 2019-09-06 | Astrazeneca Ab | 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子 |
| US11542316B2 (en) | 2017-01-04 | 2023-01-03 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | S-Arrestin peptides and therapeutic uses thereof |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| TW202021983A (zh) * | 2018-09-21 | 2020-06-16 | 美商安納普提斯生物公司 | 用於嗜伊紅性氣喘之抗il-33療法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3946256B2 (ja) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン５受容体α鎖に対する抗体 |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| WO2001060405A1 (en) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CA2542042A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition specifically binding to il-5 receptor |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| WO2008143878A1 (en) * | 2007-05-14 | 2008-11-27 | Medimmune, Llc | Methods of reducing eosinophil levels |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| KR20140015150A (ko) * | 2009-11-18 | 2014-02-06 | 메디시노바, 인크. | 급성 악화성 천식의 치료 및 이로부터 고통받는 환자의 입원 가능성의 감소 |
| EP3447491A3 (en) * | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
| EP2710370A4 (en) * | 2011-05-18 | 2015-01-07 | Medimmune Llc | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS |
| WO2013066780A2 (en) * | 2011-11-01 | 2013-05-10 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
| PL3033104T3 (pl) * | 2013-08-12 | 2019-09-30 | Astrazeneca Ab | Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu |
| CA2918050C (en) * | 2013-08-12 | 2023-10-03 | Medimmune, Llc | Methods for improving asthma symptoms using benralizumab |
-
2014
- 2014-08-07 PL PL14835826T patent/PL3033101T3/pl unknown
- 2014-08-07 SM SM20190163T patent/SMT201900163T1/it unknown
- 2014-08-07 MX MX2016001383A patent/MX368508B/es active IP Right Grant
- 2014-08-07 KR KR1020167006559A patent/KR102390714B1/ko active Active
- 2014-08-07 PT PT14835826T patent/PT3033101T/pt unknown
- 2014-08-07 WO PCT/US2014/050080 patent/WO2015023504A1/en not_active Ceased
- 2014-08-07 JP JP2016534614A patent/JP6746495B2/ja active Active
- 2014-08-07 LT LTEP14835826.0T patent/LT3033101T/lt unknown
- 2014-08-07 CN CN202010449434.5A patent/CN111588848A/zh active Pending
- 2014-08-07 DK DK14835826.0T patent/DK3033101T3/en active
- 2014-08-07 KR KR1020227013308A patent/KR20220057637A/ko not_active Ceased
- 2014-08-07 BR BR112016002401A patent/BR112016002401A8/pt not_active Application Discontinuation
- 2014-08-07 RS RS20190305A patent/RS58404B1/sr unknown
- 2014-08-07 US US14/453,942 patent/US9441037B2/en active Active
- 2014-08-07 HK HK16109784.3A patent/HK1221644A1/zh unknown
- 2014-08-07 TR TR2019/03312T patent/TR201903312T4/tr unknown
- 2014-08-07 HK HK16113684.6A patent/HK1225302B/en unknown
- 2014-08-07 AU AU2014306956A patent/AU2014306956B2/en active Active
- 2014-08-07 HR HRP20190405TT patent/HRP20190405T1/hr unknown
- 2014-08-07 EP EP14835826.0A patent/EP3033101B1/en active Active
- 2014-08-07 SG SG10202005560UA patent/SG10202005560UA/en unknown
- 2014-08-07 ES ES14835826T patent/ES2716906T3/es active Active
- 2014-08-07 HU HUE14835826A patent/HUE042607T2/hu unknown
- 2014-08-07 CA CA2918105A patent/CA2918105C/en active Active
- 2014-08-07 RU RU2016108723A patent/RU2676333C2/ru active
- 2014-08-07 CN CN201480043448.XA patent/CN105451760A/zh active Pending
- 2014-08-07 SG SG11201600481UA patent/SG11201600481UA/en unknown
- 2014-08-07 SI SI201431109T patent/SI3033101T1/sl unknown
- 2014-08-07 ME MEP-2019-75A patent/ME03348B/me unknown
-
2016
- 2016-09-02 US US15/255,508 patent/US20170198049A1/en not_active Abandoned
-
2019
- 2019-03-12 CY CY20191100294T patent/CY1122132T1/el unknown
-
2020
- 2020-02-24 AU AU2020201327A patent/AU2020201327A1/en not_active Abandoned
- 2020-04-03 JP JP2020067797A patent/JP2020128375A/ja not_active Withdrawn
-
2022
- 2022-06-07 JP JP2022092216A patent/JP2022120009A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108991A patent/JP2024129139A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202005560UA (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| IL240215A0 (en) | Methods for the purification of messenger RNA | |
| PT3305778T (pt) | Inibidores de calicreína plasmática | |
| PL3033336T3 (pl) | Inhibitory kalikreiny w plaźmie | |
| PL3033332T3 (pl) | Bicykliczne inhibitory kalikreiny osoczowej | |
| EP3123173A4 (en) | Methods for suppressing cancer by inhibition of tmcc3 | |
| IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
| SG11201600484TA (en) | Methods for improving asthma symptoms using benralizumab | |
| ZA201507475B (en) | Method for the treatment of gas | |
| IL237862A0 (en) | Methods to reduce the formation of scale | |
| GB201305231D0 (en) | Method of Manufacture | |
| ZA201601775B (en) | Method for the synthesis of irinotecan | |
| GB201301125D0 (en) | Methods for improving the efficency of gene targeting | |
| PT2799426T (pt) | Novo processo para a síntese de aminaftona | |
| IL241475A0 (en) | method for synthesis | |
| GB201316400D0 (en) | Methods, compositions and kits for preparing sequencing library | |
| SG10201701021XA (en) | Method of synthesis | |
| GB201319952D0 (en) | Methods of isolating ions | |
| GB201308949D0 (en) | Compositions and methods for reducing methane production | |
| GB201311291D0 (en) | Method of manufacture | |
| GB201301262D0 (en) | Method of manufacture |